

Treatment of diverticulitis in patients with weekend immune systems

Published: 30-04-2025

Last updated: 22-05-2025

To evaluate the disease course of diverticulitis in immunocompromised patients to determine a safe and effective treatment strategy.

Ethical review	Not available
Status	Pending
Health condition type	Gastrointestinal inflammatory conditions
Study type	Observational non invasive

Summary

ID

NL-OMON57523

Source

Onderzoekspitaal

Brief title

Conservative versus surgical treatment of diverticulitis in immunocompromised patients

Condition

- Gastrointestinal inflammatory conditions

Synonym

Diverticulitis

Research involving

Human

Sponsors and support

Primary sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Source(s) of monetary or material Support: Eerste geldstroom (geld van Ministerie van OC&W aan universiteiten)

Intervention

- Other intervention

Explanation

N.a.

Outcome measures

Primary outcome

Mortality

Secondary outcome

Adverse events
Number of admissions
Total length of admission
Length of follow-up
Surgical interventions

Study description

Background summary

Diverticulitis is an inflammatory condition affecting the colon and is treated in accordance to the modified Hinchey classification expectatively, conservatively with antibiotics or surgically with percutaneous drainage or targeted resection of the colon. There is ample evidence to support treatment modalities in healthy adults, however for immunocompromised patients the most effective treatment strategy remains unclear. In this retrospective single-center cohort study we aim to evaluate the disease course of immunocompromised adults and compare it to the disease course of previously healthy patients. We find this will provide us with information necessary to determine the most effective and safe treatment strategy.

Study objective

To evaluate the disease course of diverticulitis in immunocompromised patients to determine a safe and effective treatment strategy.

Study design

Retrospective cohort study.

Intervention

Disease course of diverticulitis

Study burden and risks

None, patients will not be exposed to treatment and will not be approached for questionnaires.

Contacts

Scientific

Erasmus MC, Universitair Medisch Centrum Rotterdam
P.R.C. de Jong
Dr. Molewaterplein 30
Rotterdam 3015 GD
Netherlands
0107040704

Public

Erasmus MC, Universitair Medisch Centrum Rotterdam
P.R.C. de Jong
Dr. Molewaterplein 30
Rotterdam 3015 GD
Netherlands
0107040704

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Patients who were diagnosed with diverticulitis between 01-01-2017 and 01-03-2025

Exclusion criteria

Age < 18

Poor understanding of Dutch or English language

Study design

Design

Study phase:	N/A
Study type:	Observational non invasive
Intervention model:	Other
Allocation:	Non-randomized controlled trial
Masking:	Open (masking not used)
Control:	Other type of control
Primary purpose:	Treatment

Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	01-05-2025
Enrollment:	300
Duration:	72 months (per patient)
Type:	Anticipated

Medical products/devices used

Product type:	N.a.
---------------	------

IPD sharing statement

Plan to share IPD: Yes

Plan description

Only anonymized data will be shared regarding age, gender and disease course. The data will be available with publication of the research. Data will be obtained using the electronic patient dossiers, and will be stored in a safeguarded database.

Ethics review

Not available

Date: 01-05-2025

Application type: First submission

Review commission: Validatie nWMO registratie door CCMO

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
Research portal	NL-009974